5 February 2025 in Molecular Cancer Therapeutics
Mutations in the tyrosine kinase domain of the anaplastic lymphoma kinase (ALK) oncogene in neuroblastoma occur most frequently at one of three hotspot amino acid residues, with the F1174* and F1245* variants conferring de novo resistance to first- and second-generation ALK inhibitors, including crizotinib and ceritinib. Lorlatinib, a third-generation ALK/ROS1 inhibitor, overcomes de novo resistance and induces complete and sustained tumor regressions in patient-derived xenograft models unresponsive to crizotinib. Lorlatinib has now completed phase 1 testing in children and adults with relapsed/refractory ALK-driven neuroblastoma and entered pivotal phase 3 testing within the Children’s Oncology Group. To define mechanisms underlying the superior activity of lorlatinib, we utilized a chemical proteomics approach to quantitatively measure functional kinome dynamics in response to lorlatinib and crizotinib in clinically relevant ALK-driven neuroblastoma patient-derived xenograft models. Lorlatinib was a markedly more potent inhibitor of ALK and preferentially downregulated several kinases implicated in G2/M cell-cycle transition compared with crizotinib. Lorlatinib treatment also led to the repression of MYCN expression and its occupancy at promoters of the same G2/M kinases. These data provide mechanistic insight into the superior efficacy of lorlatinib over crizotinib for the treatment of ALK-driven neuroblastoma.
1 April 2020 in Biochimica et Biophysica Acta (BBA) - General Subjects
Imatinib mesylate (imatinib) is the first-line treatment for newly diagnosed chronic myeloid leukemia (CML) due to its remarkable hematologic and cytogenetic responses. We previously demonstrated that the imatinib-resistant CML cells (Myl-R) contained elevated Lyn activity and intracellular creatine pools compared to imatinib-sensitive Myl cells. Stable isotope metabolic labeling, media creatine depletion, and Na+/K+-ATPase inhibitor experiments were performed to investigate the origin of creatine pools in Myl-R cells. Inhibition and shRNA knockdown were performed to investigate the specific role of Lyn in regulating the Na+/K+-ATPase and creatine uptake. Inhibition of the Na+/K+-ATPase pump (ouabain, digitoxin), depletion of extracellular creatine or inhibition of Lyn kinase (ponatinib, dasatinib), demonstrated that enhanced creatine accumulation in Myl-R cells was dependent on uptake from the growth media. Creatine uptake was independent of the Na+/creatine symporter (SLC6A8) expression or de novo synthesis. Western blot analyses showed that phosphorylation of the Na+/K+-ATPase on Tyr 10 (Y10), a known regulatory phosphorylation site, correlated with Lyn activity. Overexpression of Lyn in HEK293 cells increased Y10 phosphorylation (pY10) of the Na+/K+-ATPase, whereas Lyn inhibition or shRNA knockdown reduced Na+/K+-ATPase pY10 and decreased creatine accumulation in Myl-R cells. Consistent with enhanced uptake in Myl-R cells, cyclocreatine (Ccr), a cytotoxic creatine analog, caused significant loss of viability in Myl-R compared to Myl cells. These data suggest that Lyn can affect creatine uptake through Lyn-dependent phosphorylation and regulation of the Na+/K+-ATPase pump activity. These studies identify kinase regulation of the Na+/K+-ATPase as pivotal in regulating creatine uptake and energy metabolism in cells.
6 October 2026 in Molecular Cancer Therapeutics
Resistance to endocrine therapy (ET) is common in estrogen receptor–positive (ER+) breast cancer. Multiple studies have demonstrated that upregulation of MAPK signaling pathways contributes to ET resistance. Herein we show that vandetanib treatment suppresses MAPK signaling and enhances sensitivity to ET across ET-sensitive and ET-resistant ER+ cell lines and patient-derived organoids (PDO). Vandetanib treatment reprograms transcription toward a less proliferative, more estrogen-responsive luminal A–like state by enriching ERα chromatin binding at canonical estrogen response elements. Multiplexed kinase inhibitor bead–mass spectrometry revealed kinase network reprogramming, including upregulation of PI3K and HER2 activity, as shared adaptive resistance mechanisms to vandetanib treatment. Cotreatment with the HER2 inhibitor lapatinib further enhanced sensitivity to vandetanib. Using an operating room-to-laboratory short-term ex vivo assay coupled to single-cell RNA sequencing, we demonstrate conserved gene expression changes in primary tumor cells, including increased HER2 activity signatures, following vandetanib treatment. Vandetanib sensitivity signatures were generated from cell line and primary human tumor cells which correlate with vandetanib sensitivity in ER+ PDO and patient-derived xenograft models. Future studies should evaluate whether signatures predict responses in patients with ER+ breast tumors and determine the role of cotargeting HER2 signaling with vandetanib therapy.
20 December 2024 in bioRxiv
Resistance to endocrine therapy (ET) is common in estrogen receptor-positive (ER+) breast cancer. Multiple studies have demonstrated that upregulation of MAPK signaling pathways contributes to ET resistance. Herein we show that vandetanib treatment suppresses MAPK signaling and enhances sensitivity to ET across ET-sensitive and ET-resistant ER+ cell lines and patient derived organoids. Vandetanib treatment reprograms transcription toward a less proliferative, more estrogen responsive, Luminal-A like state by enriching ERα chromatin binding at canonical estrogen response elements. Multiplexed kinase inhibitor beads-mass spectrometry (MIB/MS) revealed kinase network reprogramming, including upregulation of PI3K and HER2 activity, as shared adaptive resistance mechanisms to vandetanib treatment. Co-treatment with the HER2 inhibitor lapatinib, further enhanced sensitivity to vandetanib. Using an operating room-to-laboratory short-term ex-vivo assay coupled to single-cell RNA sequencing, we demonstrate conserved gene expression changes in primary tumor cells, including increased HER2 activity signatures, following vandetanib treatment. Vandetanib sensitivity signatures were generated from cell line and primary human tumor cells which correlate with vandetanib sensitivity in ER+ patient-derived organoid and xenograft models. Future clinical trials of vandetanib in ER+ breast cancer should include rationally designed co-treatments based on adaptive resistance pathways, including HER2, and evaluate response signatures as biomarkers predicting patients most likely to benefit. SIGNIFICANCE: Vandetanib enhances sensitivity to tamoxifen in ER+ breast cancer by reprograming ERα gene regulation and kinase signaling networks which define gene expression signatures associated with response and identify targetable adaptive resistance pathways.
14 August 2026 in Cancer Research
The development and validation of prognostic and predictive biomarkers in breast cancer are limited by the availability of well-annotated datasets linking tumor molecular features to treatment response and survival outcomes. To address this need, we generated an extensive mouse model dataset comprised of 26 immunocompetent mammary tumor models spanning diverse genetic backgrounds, epithelial–mesenchymal states, the basal–luminal axis, and distinct immune microenvironments. For each model, survival was measured under no treatment, immune checkpoint inhibition (ICI), and carboplatin/paclitaxel chemotherapy, and RNA sequencing was performed on baseline tumors and on 7-day on-treatment samples for both regimens. Baseline murine tumor gene expression features were used to train a machine learning elastic net model that predicted survival outcomes on multiple human breast cancer datasets with performance comparable with that of existing prognostic assays. Models trained for ICI benefit, using either the untreated or 7-day ICI-treated samples, predicted ICI benefit on human ICI-treated datasets, with the 7-day treated tumor model showing better performance. A predictor of carboplatin/paclitaxel response developed from the murine mammary tumor data performed well in mice but did not generalize to human chemotherapy cohorts. Finally, comparison of multiple computational approaches, including XGBoost, random forests, and support vector regression, showed that all methods successfully predicted survival outcomes, with elastic net offering the best performance and interpretability. These results indicate conserved cancer biology between mouse and human tumors for prognosis and ICI response and establish a large preclinical dataset with linked phenotypic and genomic data as a resource for biomarker discovery. Significance: The development of a genomically and phenotypically diverse murine tumor dataset with linked treatment outcomes establishes a robust translational resource to develop, test, and benchmark clinically relevant prognostic and therapeutic response biomarkers.